Wednesday, March 9, 2011

The 7 stages of an adviser-student relationship

I'm going to sign your thesis... someday.
Photo credit: Ozone Ferd
Stage 1: (1st year, senior undergraduates) "Professor X is so smart. I'm honored to be in his presence."
Stage 2: (2nd year) "Professor X doesn't care about me."
Stage 3: (3-4 year) "Professor X hates me and only me."
Stage 4: (4-5 year) "I $#$#$#$# hate Professor X. He's a complete ^@#@#!"
Stage 5: (5 year+) "I'm so tired of Professor X. I'm so ready to be done."
Stage 6: (post-graduation) "Professor X isn't so bad. He's a lot better than Professor Y."
Stage 7: (2 years post-graduation) "You know, that Professor X, he's grown a lot since I left the group."

Process Wednesday: Scale-up questions

The Kilomentor blog is a really great and under-referenced resource in the chemistry blogosphere. He has a great list of questions for anyone looking to scale up a reaction. He asks incisive questions about difficulties that might arise during crystallization, filtration, drying and today's topic, extraction. Does the process have an extraction step(s)? If so:
  1. Are the phases susceptible to emulsion formation (vigorous shaking)?
  2. What provisions for promoting separation are known?
  3. Are the phases very dark and hard to tell apart? What to do?
  4. What about interfacial material? What should be done with it?
  5. Have you reduced the size of the liquid phases as much as possible to increase throughput?
I have worked under conditions of question 3, where phases are extremely difficult to tell apart. While it's difficult, it's not too tough on 22-liter scale (especially when you can watch/hear the solution coming out of the separatory funnel.) I cannot imagine what one does when the scale is increased significantly (shudder.)

Interfacial material is another weird one. What to do with the stuff? It's both organic and aqueous. I've never found a good answer to this question. (I guess it depends on its purity; there's gotta be a lot of inorganic salts in there, but if you're short on product, you might be tempted to try to recover it.) Readers?

Tuesday, March 8, 2011

Thanks, NYT, for that cheering news on pharma.

You weren't looking to support me, were you?
Photo credit: missginsu.com
On Sunday, the New York Times had a sobering analysis of the problems of the pharmaceutical industry. Some key quotes follow, with my emphasis:
This is a sobering reversal for an industry that just a few years ago was the world’s most profitable business sector but is now under pressure to reinvent itself and shed its dependence on blockbuster drugs. And it casts a spotlight on the problems drug companies now face: a drought of big drug breakthroughs and research discoveries; pressure from insurers and the government to hold down prices; regulatory vigilance and government investigations; and thousands of layoffs in research and development.

[snip] The same concerns apply to drug giants in the United States. They are all struggling with research failures as they scramble to replace their cash cows, like Pfizer’s multimillion-dollar gamble on a replacement for the cholesterol-lowering drug Lipitor, which failed miserably in clinical trials. Drug companies cut 53,000 jobs last year and 61,000 in 2009, far more than most other sectors, according to the outplacement company Challenger, Gray & Christmas.
“This is panic time, this is truly panic time for the industry,” said Kenneth I. Kaitin, director of the Center for the Study of Drug Development at Tufts University in Medford, Mass. “I don’t think there’s a company out there that doesn’t realize they don’t have enough products in the pipeline or the portfolio, don’t have enough revenue to sustain their research and development.”
 
[snip] “We have to fix our innovative core,” Pfizer’s new president, Ian C. Read, said in an interview recently. To do that, the company is refocusing on smaller niches in cancer, inflammation, neuroscience and branded generics — and slashing as much as 30 percent of its own research and development spending in the next two years as its scientists work on only the most potentially profitable prospects.
 
[snip] “You don’t lay off R&D if it’s just a cycle,” says Erik Gordon, a clinical assistant professor at the University of Michigan business school who follows the pharmaceutical industry. “That kills progress.”
 
[snip] At the same time, pharmaceutical companies are being urged by managed care and government health programs to cut prices and improve reimbursement terms for their most profitable pills.That follows similar practices in Europe, where Germany and the Britain, among other countries, are all increasing pressure for lower drug prices.

“Europe is an ugly place to do business today and will be in five years’ time,” Christopher A. Viehbacher, chief executive of the French drug giant Sanofi-Aventis, said in an interview. In the United States, Mr. Viehbacher said generic drugs were taking over the primary care market, leaving the best growth potential in specialty markets and in emerging nations like China, Brazil and Indonesia.
Huh. Well, that's not good news.* Materials science, anyone?
 
A bold prediction: rock bottom for pharma will be sometime next year (2Q 2012?). After that, we're going to have a changed industry with pullouts, layoffs and retrenchments between now and then. And then? We'll probably have a little hiring here and there. But between now and then, there will be blood.
 
*For extra awesome, read the comments to the article. Truly a joy.

Carbohydrate/analytical chemist wanted for Southeastern US company

Our recruiting friend Lisa is looking for another chemist in the Southeastern United States.

You: a Ph.D. chemist with 0-3 years experience in "[i]ndustrial or post-doctoral research experience (0-3 years) and previous experience with modification and analysis of sugars or starches and mass spectroscopy." Project management experience a must. Will participate in research towards "developing new technologies and new products in surgical adhesives, hemostatic agents and implantable biomaterials, and supports existing products and technologies."

Sounds like fun. E-mail Lisa at lcrawford -at- appleone/dot/com.

Daily Pump Trap: 3/8/11 edition

Good morning! Between March 4 and March 7, there were 44 new positions posted on the ACS Careers database. Of these, 17 (39%) are academically connected.

Your subjects won't cry: Dow Agrosciences is looking (at the ACS conference in Anaheim) for B.S., M.S. and Ph.D. synthetic chemists. Indianapolis is a pretty nice town (really!) and Manning has a least a couple more years in him.

Uh, you could pay more, right?: Cambridge Major Laboratories is looking for a Ph.D. chemist with 5-10 years of "real-life, industrial experience preferably in an API facility." So why are you paying 60k to 80k? I mean, I'm sure that Germantown is a nice town with a low cost of living, but is it really that low? (Readers, amicrazyhere?)

Coatings: Arkema is looking for a Ph.D. polymer chemist with experience in coatings formulation; the position is in King of Prussia, Pennsylvania. (You, presumably, will become the King or Queen of Coatings.)

Hey, you again!: Halcyon Molecular is looking for a M.S./Ph.D. analytical chemist with experience in gel-filtration and ion-exchange chromatography. Bay Area candidates preferred.

Pune!: Nalco is searching for a M.S. chemists with experience in oilfield chemicals; the position is in (wait for it...) Pune, India. I'll note that Nalco is the first employer to append a YouTube video with their ad -- so you got that going for you. What's the job growth difference between the developing world and the US? Well, Nalco is hiring 15 positions there. Fifteen!

Monday, March 7, 2011

So chemists are safe from the intelligent computer menace, right? Right?

Chart authors: Autor, Levy and Murname
Credit: Paul Krugman, New York Times
While super-smart computers have been beating Jeopardy champions recently, they've been putting lawyers out of work as well. This fascinating New York Times article points to computer programs that can perform "document discovery" services that used to require auditoriums (literally) of lawyers poring over documents. More neat (and or freaky) are computer programs designed to analyze e-mail for "off-the-record" conversations, i.e. the moment when you decide to stop an e-mail chain and walk down the hall and have a private conversation.

In blogposts on this issue, Paul Krugman points to a paper by economists Autor et al. that summarizes the tasks that computers can either replace or complement humans. If you see the top right section ("non routine", "analytic and interactive tasks"), it appears that chemists ("forming/testing hypotheses") are going to be safe for now from productivity gains from working with computers. It is interesting how Krugman suggests that "medical diagnoses" may ultimately move from the right to the left column. Is Watson going to put general practitioners out of work? We shall see....

An interesting contrast

Madeleine Jacobs, the CEO of the American Chemical Society, last year in her "2010 highlights" C&EN column:
We are well into 2010, and I would like to share what we are emphasizing this year. When people ask me what keeps me up at night, I tell them it is the fragile economy and high unemployment rates that our members and the U.S. in general are experiencing. I have lived through five major recessions in the U.S., and there is nothing more heart-wrenching to me than to talk with talented chemists and chemical engineers who have lost their jobs and wonder what the future holds for them. ACS will continue to focus on the needs of all our members, with a special focus on our unemployed members. In addition, we are actively pursuing opportunities to work with Congress and the Obama Administration to keep valuable jobs in the U.S. and to help our chemists start and be successful in new businesses.
Madeleine Jacobs, this year (emphasis CJ's):
We are already well into 2011—the International Year of Chemistry. I am thrilled that chemists finally have our year to celebrate, but my elation is tempered by the continued sluggishness of the economy. Many sectors of the economy are improving, and the chemical industry is showing substantial profits, but we are still not seeing hiring of chemists at a fast enough pace. I have lived through five recessions in the chemical industry, and, until this last recession, we always experienced a reasonable recovery that involved adding back jobs that were lost in R&D. In this recession, everyone in the chemistry enterprise suffered, but unlike previous recessions, many people agree that we have experienced a paradigm shift and that jobs in R&D will not be substantially recovered in this country. 
We will continue, therefore, to coordinate, prioritize, and enhance ACS services to help members succeed in this rapidly changing and globalizing workplace. Efforts will likely include offering an integrated package of prioritized career development services, disseminating enhanced market intelligence to members on workplace trends, improving member awareness of services, and exploring new efforts to facilitate chemistry-related job creation via small-business and start-up innovation. 
As always, I am interested in hearing from you. What do you think ACS should be doing to help our members and the chemistry enterprise thrive? Please write me at m_jacobs@acs.org.
While I could offer snarky comments, I won't. I'll just say that I am glad that Ms. Jacobs is seeming to face the music that her members have been dancing to for about 2 years now.  I also await (with eagerness) the changes that are to come to ACS' member services with regards to solving the employment problem. See you (on this subject) this time next year.  

Saturday, March 5, 2011

Blue label tape

A collection of small useful things (links):

Staff scientists in academia?

I'm guessing that most chemblogosphere denizens have read Dr. Jennifer Rohn's piece suggesting the formation of professionalized staff scientists in labs rather than itinerant postdocs. Derek Lowe has an interesting and (more direct than usual) response to Rohn, which I'm sure most have read as well. A few thoughts of my own:

Why no reference to Benderly? On this blog, we've been through discussions of staff scientists / professional postdocs before, during our discussion of Beryl Lieff Benderly's article "The Real Science Gap." Rohn's argument is quite similar to Benderly's -- I'm surprised that there wasn't a note about it. (Similar enough that Benderly dryly notes that it's nice to hear a new voice say the same things.)

For that matter, Rohn's (IMO correct) assertion that a tournament model is working in the academic labor market was also covered by Benderly in November. (It should be noted that the tournament concept is most attributable to economist Prof. Richard Freeman.)

What is the state of the industrial biology job market? The surfeit of academic postdocs is clearly the result of the mountains of NIH funding -- in particular, for biomedical research. It appears that, in contrast to chemistry, there is less of an industrial escape valve in the biomedical sciences to take up the surplus of workers; Lowe's final comment seems to indicate as such. This comment on In the Pipeline suggests that, in pharmacology, that industry has adapted to the new reality by requiring more and longer postdoctoral stints of their candidates. Terrifying.

At the same time, the number of medical scientists is expected to grow significantly (see slide 11), according to the US Bureau of Labor Statistics. 39.3%, to be exact, between 2008-2018. One wonders where they're all going to come from and where they're going to work.

A negative feedback loop: Dr. Rohn's core idea is expressed in the following paragraph:
An alternative career structure within science that professionalizes mature postdocs would be better. Permanent research staff positions could be generated and filled with talented and experienced postdocs who do not want to, or cannot, lead a research team — a job that, after all, requires a different skill set. Every academic lab could employ a few of these staff along with a reduced number of trainees. Although the permanent staff would cost more, there would be fewer needed: a researcher with 10–20 years experience is probably at least twice as efficient as a green trainee. Academic labs could thus become smaller, streamlined and more efficient. The slightly fewer trainees in the pool would work in the knowledge that their career prospects are brighter, and that the system that trains them wants to nurture them, not suck them dry and spit them out.
So far as I can tell, this is a negative feedback loop. As more staff scientists are hired, there will be less funding available for postdoctoral fellows and graduate students. I believe that Dr. Rohn sees this as a feature, not a bug. Most current scientists would agree, I suspect.

But here's the thing: society, through the government, wants lots of scientists. They don't care about scientist unemployment -- they care about curing diseases and getting more for their taxpayer dollar. That un(der)employed scientists are the negative externality of massive NIH funding is not their concern -- we're just the grist. I suspect our cries will fall on deaf ears. 

Friday, March 4, 2011

This is just to say...

A poem, by Chemjobber:

This is just to say
that I had a busy morning
and I was not able to blog today
Forgive me
The hours are short
And real work is plentiful

with apologies to William Carlos Williams.

(back tomorrow AM with today's posts -- I promise)

BREAKING: Unemployment rate down to 8.9%, from January's 9.0%

Fresh (not so fresh) electrons from BLS. The unemployment rate is at 8.9%, down from January's 9.0%. U6 unemployment also slightly down to 15.9%, from January's 16.1%. More later. 

Thursday, March 3, 2011

What is the most common personality trait of leaders in chemistry organizations?

Don't you remember? I was captain of the team.
Photo credit: latinoreview.com

If you spend any amount of time in chemistry, it doesn't take long before you realize the different personality types that populate the laboratory jungle. Most of us, for one reason or another, aren't particularly extroverted. Sure, there are our moments when we pop out of our shells or that we decide that here, now, we're going to make our stand on some issue. But that's the exception, rather than the rule. The vast majority of chemists in any gathering or organization will keep their mouths shut, even in the face of the most angering statements or the most heartfelt pleas for feedback.

At the same time, you do see people who have a certain amount of personal force*, who are assertive in their speech and confident in their actions. Oddly (or perhaps not), they're the folks who always seem to end up in industry management and leadership.

In my experience, this personality trait is not limited to Casper Van Diem's (see right) gender. I have worked for a few women in my time in industry; they were just as self-confident as any man might be.

So here's my lab postulate of the week: in any gathering or organization of chemists, the agenda is most likely to be set not by the most productive or competent person, but by the most outspoken or extroverted person present.

Readers, what do you think? Am I right or wrong?

*To borrow a phrase from "The Godfather."

Daily Pump Trap: 3/3/11 edition

Good morning! Between March 1 and March 3, there were 20 new positions posted on the ACS Careers website. Of these, 1 (5%) is academically connected.

Wanna live in Houston?: Celanese is a Fortune 500 polymer company. They've posted 11 positions, all interviewing at ACS Anaheim later this month. Chemists (with experience), chemical engineers, it's all there. Good luck!

Or Connecticut?: ITW Trident is (apparently) a company that works on inkjet products. They'd like a M.S./Ph.D. chemist with experience in ink formulation to "help formulate and develop inks and fluid products for new and existing printing systems as determined by customer and market requirements from feasibility phase to product launch." Is the salary a little skimpy for CT? Magic 8-Ball says "Signs point to yes."

How about D.C.? Or maybe Davis, CA?: TSG is a regulatory compliance consulting firm; they're looking for a Ph.D. chemist for work on "[s]tudy design and review, especially for FIFRA and FDA." Experience with GMP/GLP and FIFRA (what's that?) and PMRA (among others) a plus.

How about Palmdale -- it's a nice town (?): ERC is the contractor for the Air Force Research Laboratory at Edwards Air Force Base. It's a lot of desert out there, lemme tell ya. They're looking for a B.S. chemist. "Specific experience in polymer nanocomposites is desired. A strong candidate would have organic or inorganic synthesis experience and the desire to learn monomer/polymer characterization techniques including GPC, TGA, DSC, NMR, SEM, AFM, as well as the use of analytical lab equipment. Experience with nanoparticle and/or polymer synthesis would also be beneficial. Competitive salary offered. Applicant MUST be a U.S. citizen." This is good stuff, and there's cheap housing! (heh)

Welcome to...: ChemistryWorldJobs, which seems to focus on UK chemistry jobs. Best of luck to them, and all of us.

Wednesday, March 2, 2011

Reader poll results: predictions for the 2011 job market

Well, there it is, folks. I'm guessing that more "much worse" votes came in as news of the Pfizer layoffs (and others) arrived. 

Process Wednesday: "Ruggedness"

In the process chemistry literature, there are many words that are liked, e.g. 'simple', 'efficient'. But our mentor-by-literature Neal Anderson (and others) seem to prize the word 'rugged' or 'robust' more than most. In his book "Practical Process Research and Development", Dr. Anderson describes a rugged process as such:
A rugged or robust process must included 3 qualities: high-quality product must be prepared within the expected time cycle; the process must accommodate relatively broad purity ranges for the inputs, whether prepared or purchased; and the process must operate within parameter ranges, e.g. temperature and pH, which are readily obtainable during the expected process time-cycle. Unless the process is rugged, additional time is incurred, and the quality of the drug substances may be jeopardized. Appropriate in-process controls (IPC) are necessary to maintain low operating costs. Processes must be as simple as possible, but superficially simple (simplistic) processes may be eventually prone to errors. 
In his recent review*, the R-words pop up again:
An "edge of failure", or the conditions at which process failure will result, lies at the limits of the PAR (proven acceptable range) or beyond them at some undetermined point. After appropriate optimization a robust manufacturing process will "tolerate the expected variability of raw materials, operating conditions, process equipment, environmental conditions, and human factors."**  
In general, rugged processes operate comfortable far from the edge of failure. 
Interestingly, (completely underappreciated blog) Kilomentor has a bittersweet answer as to 'why' ruggedness may be prized in our modern times:
The Kilomentor approach to process development is geared towards the simple, rugged and dependable process step and avoids the technically demanding step, which uses sophisticated and expensive equipment. This keeps with the tenor of the times wherein so much process work is being moved to the developing economies where at least for now labour is plentiful, so long as the work process is rugged.
*Anderson, N.G.; Burdick, D.C.; Reeve, M.M. "Current Practices of Process Validation for Drug Substances and Intermediates." Org. Process. Res. Dev. 2011, 15, 162-172.
**Process Robustness - A PQRI White Paper. Pharm. Eng. 2006, 26(6), 1; http://www.pqri.org/pdfs/06ND-online_Glodek-PQRI.pdf

Tuesday, March 1, 2011

The roots of adviser rage

What do you mean, you forgot to take the crude NMR?
Photo credit: terraspirit.com
I recently heard complaints about a faculty adviser; this adviser had taken to resorting to banging on tables and walls to get their* point across.

Obviously, this is immature and wildly inappropriate (especially in the presence of subordinates.) But it seems that most chemists have either seen or heard stories of advisers losing their temper and taking it out on either physical objects and/or (verbally) their students and postdoctoral fellows.

Such behavior is probably the result of a few of different factors: 1) the stress and pressure of a faculty career, with grants and et cetera, 2) the vulnerability and pliability of subordinates (when directed at such) and 3) the knowledge that such behavior is looked at with a blind eye and more or less tolerated by their department and/or administration.

I suspect that, unfortunately, adviser rage will always be with us; while I might be able to list 2 or 3 reasons why it might go away over time, I can think of 10 reasons why it won't. While it's awful and inexcusable, it does happen. (And sometimes, there's a legitimate reason for the adviser to be frustrated.) But it is my sincere hope that (over time) university administrations and the chemistry community will come around to the thought that it's unacceptable and needs to be frowned upon. I hope I'm right.

*Look, who am I kidding? Of course it was a dude.

Many, many things we love

Goodness me, there were a lot of participants in the "12 chemistry things" I love list:
  • Leigh's list -- check out the beautiful photo.
  • Matt's list -- always nice to have the inorganic chemistry view.
  • LabMonkey's list -- funny how ethyl acetate always shows up as a favo(u)rite smell.
  • Sharon's list -- #3 is so dead on.
  • Wavefunction's list -- super thoughtful, as always. Not reading his blog? You should be.
  • Beloved commenter CMCguy's industry-inspired list.
  • Beloved commenter SeeArrOh's list -- a simple dump-and-stir is always a friend.
  • The Boiling Point's list -- the foam one is so true.
  • Fischblog's list -- "Synthesis is almost magic." Almost.
  • Kzrt the phytochemist's list. Fixing your own glassware!?!?!
  • The Scientist Next Door's list. "Tension-free project meetings." I'll have to have one of those, sometime.
Wow! Thanks for all the participation. Don't forget the all-time master list is here on ChemistryBlog.

Daily Pump Trap: 3/1/11

Good morning! And a happy March to you! Between February 24 and February 28, there have been 106 new positions posted on the ACS Careers website. Of these, 14 (13%) are academically connected.

MerckMerckMerckMerck: Of these 106 positions, fully 75 (71%) of them come from the good folks at Rahway and points elsewhere. Sure, while there sure is a position for a senior biologics chemist, there's a lot more positions for senior attorneys and command center technicians. I'm not quitting on this, by the way.

You know...: While I regard China with some level of trepidation, there is no doubt that there is money to be made. Here's an advertisement for a product manager for a scientific instrument company in China -- is there any doubt that this is one of the world's great growth markets for such?

We make the things: BASF is looking for a Ph.D. chemist or chemical engineer with a strong catalysis background; 1-3 years industrial experience desired.

Plastics: St. Gobain is looking for a Ph.D. chemist with a polymers background for a senior research associate position. Silicone chemistry experience is desired, along with 8-10 years experience. (Pssssst -- if you really want that much experience and education, shouldn't you change the title? Just sayin'.)

Monday, February 28, 2011

Interview: moving from the bench to IP work

I'm pleased to bring you an interview with someone we'll call TL, who has transitioned out of the lab into the intellectual property field. This might be another potential career path for those looking to leave the bench.

This Q&A has been lightly formatted and edited by CJ and checked for accuracy by TL.

Chemjobber: Can you describe your background a little?

TL: I always knew that I wanted to be a scientist, but it took me a few semesters of college for me to figure out what I wanted to major in. I hated chemistry in high school so I shyed away from chem as an undergrad, but I ended up taking organic chemistry, and I fell in love. As much as I enjoyed it, and my undergraduate lab experience, I knew I didn't want to work in a lab for my entire career. I went to grad school with that in mind - I thought that having a PhD would provide more career opportunities for me.

However, I wasn't sure that grad school was the place for me, so I took some time off to take a job at a biotech company and then a big pharma company, and I never looked back. I had a great career as an associate medicinal chemist. But it's hard to move ahead without a PhD, and I also saw that the industry was hurting, so I realized it was finally time for me to start exploring options outside the lab.

CJ: Your new position involves intellectual property -- how do you like it?

TL: I am now a patent examiner at the United States Patent and Trademark Office, although as someone pointed out, I'm not actually a patent examiner, I'm a patent application examiner. I am given several patent applications to read. Once I understand the invention in the application, I write a response to the applicant's attorney with an analysis of their invention, how it fits into the prior art, and whether or not it is patentable. The goal is to help the applicant claim what is rightfully theirs without infringing upon others.

My role as a patent examiner has been a great way for me to use my scientific background in a new way. I like seeing what people are working on across a variety of disciplines, and every day I get to read about something new. Some days I read about medicinal chemistry related art, but some days I read about different diseases or cosmetic treatments or food additives. I enjoy the challenge of understanding art that I am not familiar with, and understanding the problems and how people are trying to improve upon the current technology.

There are a lot of benefits to the job, but the best part of the job is the amount of training and mentoring they provide. They want their employees to succeed. Of course they have their own reasons for helping you - it's a business, even if it's a government agency - but I can't remember the last time my employer made such efforts to not only develop the skills I need to complete my job, but to outline potential career paths at USPTO or with the federal government. The training program is extensive and we are given quite a bit of time to ramp up to full production.

CJ: Do you find your chemistry skills being used substantially on a day-to-day basis in your new position?

TL: There certainly isn't any wet lab work involved in patent examining. But writing an office action is similar to writing a journal article - there's a lot of formal language, you need to concisely and coherently make your argument, and there are revisions and input from your supervisor and replies from the applicant's attorney. Applications are also judged based on the state of the art at the time of the invention, so you need to have an idea of what would be known to a chemist at the time that the patent was written. We use the phrase "one having ordinary skill in the art" all the time. (CJ: a.k.a. PHOSITA)

CJ: Anything you miss about not being in the lab? Anything you don't miss?

TL: I miss crystallization - it's just so beautiful. But many of the things that I enjoyed about working in the lab - the process of creation, and the scientific process itself - I appreciate in everyday life. Many of my hobbies are hands-on and of the create-something variety. Who doesn't do a bit of experimentation and trial-and-error in the kitchen?

CJ: What would you suggest to someone interested in following your path?

TL: USPTO has a very diverse workforce - there are people of all ages and backgrounds, so there's no one right way to go about becoming an examiner. I believe 40-50% of the examiners in the chemistry and biology technology center have a PhD, and most of the rest have a master's degree. Some are right out of academia and some have industry experience. The most important thing is that you have to enjoy reading and writing about a wide variety of topics, since you aren't always going to be examining kinase inhibitors or cancer treatments or whatever your specialty may be.

Set up an automatic search on USAJOBS.gov for a patent examiner position (I bet most of your readers already have one for the keyword "chemistry") and just keep your eyes open. Job postings tend to come and go, so it's just a matter of timing.

CJ here again. Thanks so much to TL for the thoughtful and interesting conversation!

Friday, February 25, 2011

12 things I love about chemistry

Photo credit: ThinkGeek.com
This employment/unemployment stuff is rough.

1. As always, fluffy white crystals.
2. The very occasional pleasant surprise in your data.
3. The plethora of really smart folks.
4. Big complex equipment that makes your life easier.
5. Seeing that peak at the right retention time
6. That water can have so many uses: solvent, scapegoat, reagent, to cool, to warm...
7. A rousing discussion of reaction mechanisms.
8. A well-written supplemental information section.
9. When older chemists talk about life in the "good old days": smoking at the bench, ether in the sink, etc.
10. Hearing good hiring news from friends,  as in: "I got a job!"
11. (ever-so-rare) Projects that go well from beginning to end
12. The sound of samples going in and out of an NMR.


I'm tagging a few folks here: biochembelle, Leigh, ScienceGeist, ChemBark, Icanhasscience, Lab Monkey, The Haystack and Transition States. What are your favorite things? Even if I didn't name you, join in! Y'all come, so to speak.